GO
Loading...

Enter multiple symbols separated by commas

AstraZeneca PLC

More

  • June 22- The U.S. Food and Drug Administration on Monday approved Medicines Co's blood clot preventer Cangrelor, which has faced multiple setbacks since it first entered late-stage studies close to a decade back. Medicines Co has funneled about $200 million into developing Cangrelor over the past decade, which included two unsuccessful trials and a pivotal...

  • Shares of the company, whose customers include AstraZeneca Plc, General Electric Co and Chevron Corp, rose about 8 percent in extended trading on Wednesday. Box raised its full-year forecast to $286 million- $290 million from $281 million- $285 million earlier. The company's main competitors include privately held Dropbox, Microsoft Corp's OneDrive, Citrix...

  • LONDON, June 10- AstraZeneca's chief medical officer and head of global late-stage drug development Briggs Morrison is to leave the company, creating a gap at the top of the group's research operations. A spokeswoman said on Wednesday Morrison was departing to become chief executive of an unlisted venture capital-backed drugmaker in the United States,...

  • LONDON, June 10- AstraZeneca's chief medical officer and head of global late-stage drug development Briggs Morrison is to leave the company, creating a gap at the top of the group's research operations. Morrison, who joined AstraZeneca from Pfizer in 2012, has played a central role in the British drugmaker's bid to turn around its portfolio.

  • June 2- AstraZeneca Plc would consider acquiring a developer of a new type of cancer therapy aimed at supercharging the body's immune response, Bloomberg quoted Chief Executive Pascal Soriot as saying on Tuesday. An earlier version of the Bloomberg article quoted Soriot as saying that AstraZeneca would consider buying a company such as Juno Therapeutics...

  • *Dollar drops on optimism of Greece deal with creditors. *Intel drops after rating cut; biggest drag on indexes. June 2- U.S. stocks erased earlier losses to turned positive on Tuesday afternoon on optimism that Greece would strike a deal with its creditors, while weak U.S. data and bearish comments from a Federal Reserve board member allayed fears of a near-term...

  • *Juno jumps on report of AstraZeneca interest. June 2- U.S. stocks were lower in late morning trading, paring some of their losses earlier in the session, as weak factory orders data and bearish comments from a Federal Reserve board member allayed fears of a rate hike coming sooner rather than later. "Interest rates are not going to matter if they're rising because of...

  • June 2- AstraZeneca Plc would consider buying a company such as Juno Therapeutics Inc, Bloomberg reported AstraZeneca's CEO as saying, according to StreetInsider. AstraZeneca and Juno already have a collaboration agreement to test one of AstraZeneca's cancer drugs in combination with Juno's CAR-T cell therapy, which is considered to be a breakthrough in...

  • June 2- AstraZeneca Plc would consider buying a company such as Juno Therapeutics Inc, Bloomberg reported AstraZeneca's CEO as saying, according to StreetInsider. The companies were not immediately available to comment. Juno is one among the few companies that are developing a new class of immuno-oncology treatments called CAR-T cell therapies.

  • CHICAGO, June 2- Drugmakers including Bristol-Myers Squibb Co and Merck& Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said. Competitors Roche Holding, AstraZeneca and Pfizer also have similar drugs in...

  • *Roche, AstraZeneca gain on positive updates. LONDON, June 1- European shares held steady at the start of the month on Monday, with a rally in some drug stocks on the back of positive company updates offset by lingering concerns over Greece's debt situation and weaker commodity stocks. Drugmakers Roche and AstraZeneca, up 2.2 percent and 1 percent respectively,...

  • LONDON, June 1- European shares kicked off June on a positive note on Monday, helped by a rise in pharma stocks, although main indexes were still stuck in their recent range as uncertainty persisted over Greece's future. Athens and its euro zone and International Monetary Fund creditors have been locked in talks for months on a cash-for-reforms agreement.

  • Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday. The Bristol drug was approved by U.S. regulators in December to...

  • These biotechs may surge on drug news: Expert Friday, 29 May 2015 | 3:31 PM ET
    Lab science research

    Incyte stands to benefit from unveiling data on its cancer treatments at a conference in the coming days, a biotech analyst said.

  • Here's why Puma, Clovis shares are poised to move Friday, 29 May 2015 | 2:49 PM ET
    Attendees walk through the lobby at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. (File Photo).

    It's that time again. With researchers set to convene at the American Society of Clinical Oncology meeting, here are the stocks to watch.

  • New class of drugs shows promise for cancer fight Friday, 29 May 2015 | 2:18 PM ET

    A study sheds light on why the new medicines seem to work for some cancers and not others, NYT reports.

  • COPENHAGEN, May 26- Bavarian Nordic is hot property after striking two big vaccine deals but the small Danish company is not for sale, despite a wave of consolidation in the healthcare industry, its chief told Reuters. Boosting the immune system is now a top priority for cancer drug companies such as Bristol-Myers, Merck, Roche and AstraZeneca, fuelling renewed...

  • Early movers: TWC, AAPL, CTRP, CRM, GM & more Tuesday, 26 May 2015 | 7:54 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • LONDON, May 26- AstraZeneca's hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller. AstraZeneca and Amgen have been sharing development of brodalumab since 2012 as a treatment for psoriasis, psoriatic arthritis and axial...

  • May 22- Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial. AstraZeneca could decide on the development and marketing of the drug for all territories, except for Japan and certain Asian territories, where Kyowa Hakko Kirin has the rights to it, Amgen said.